Juliana M. Reed

BioTech

PBMs aren’t opening access to lower-cost biosimilars. Reform is needed now

The Federal Trade Commission presents on Thursday its interim staff report, “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies.” It

Juliana M. Reed August 1, 2024

BioTech

A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches.

Juliana M. Reed February 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Juliana M. Reed

PBMs aren’t opening access to lower-cost biosimilars. Reform is needed now

A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe